Shares of Verastem Oncology (VSTM -8.67%), a biotechnology company developing novel cancer therapies, are sliding after a highly anticipated data drop failed to impress investors. Shares of the biotech stock were down 42.9% as of 12:12 p.m. EDT on Monday.
This year, the American Association for Cancer Research granted independent researchers who have been testing a combination of Verastem's experimental therapies a virtual poster presentation during this year's meeting. Verastem shares ballooned last week after the company told investors it would hold a conference call today to discuss results of an independently sponsored clinical trial that used VS-6766 plus defactinib to treat cancer patients with aggressive tumors driven by the same mutation.
The stock is tanking today because there wasn't much to be excited about, at least from an investor's viewpoint. Among 10 lung cancer patients in the study with KRAS-mutant tumors, just 1 showed signs of tumor shrinkage.
Tumors driven by KRAS mutations are difficult to treat, but not for lack of trying. Amgen (AMGN -0.34%) and Mirati Therapeutics (MRTX -2.52%) are both running clinical trials with drugs aimed at this target, and both have notched a great deal more success than Verastem's candidates.
Despite seemingly unbeatable competition from Amgen and Mirati for lung cancer patients, Verastem will probably try to convince investors there's a future for VS-6766 as an ovarian cancer treatment. Four out of six patients with KRAS-mutant-positive ovarian cancer responded to treatment with VS-6766 plus defactinib.